Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prefilled autoinjector Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

NCT05337345
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cendakimab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

NCT01984424
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

NCT00958009
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebidose®
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

NCT01849497
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

NCT07133191
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Selatogrel, Matching placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
20 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

NCT01854918
View directory record Official record
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Interventions
Evolocumab, Standard of Care
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
107
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

NCT06114238
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab AI, Itepekimab PFS
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

NCT02636907
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501 Autoinjector, BI 695501 Prefilled syringe
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Upland, California • Venice, Florida • Cumberland, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

NCT05306275
View directory record Official record
Conditions
Healthy Participants
Interventions
CSL312
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 17, 2026, 2:30 PM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

NCT01610310
View directory record Official record
Conditions
Healthy, Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 17, 2026, 2:30 PM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991
View directory record Official record
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Etanercept / Autoinjector A
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06224192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab Prefilled Syringe, Rocatinlimab AI
Combination Product
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
22
States / cities
Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

NCT01890473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Huntsville, Alabama • Centennial, Colorado • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

NCT02660736
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

NCT01879319
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab AMD, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

NCT03918239
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP643
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 17, 2026, 2:30 PM EDT